Search 

A startup biotech focusing on novel therapeutic antibody discovery and development, particularly in fully human nanobody and bispecifics. Recently closed a Series A fund raising (USD $25M ).

苏州博奥明赛生物制药有限公司是一家专注于创新生物大分子药的研发型公司。公司已经建立起了多个国际领先的全人源快速抗体发现与优化平台，其中包括国际领先的全人源纳米抗体和双特异性抗体平台以及国际上库容量最大的噬菌体，酵母菌，和哺乳动物细胞展示平台。公司依托平台优势，在较短的时间内已经拥有十多个在研全新生物大分子药物，包括多个国际上首创的全人源纳米抗体（VH）和双特异性抗体。本轮融资资金将主要用于推进其中两个先导项目的临床前开发。

Bionus Biotechnology was established in 2018， with an angel investment of a Finnish Company Currently we have 15 team members, 10 full-time, and 100% master's degree or above. Bionus has in-depth cooperation with the Karolinska Institute , Tokyo Medical and Dental University and Machine Learning Tokyo, the core members of the team had the background of Nobel Prize laureate in 2018, Mr. Tasuku Honjo.

The team currently covers 2 major layouts (AI-assisted small molecule chemical drug screening and creation of new peptide vaccines), 6 types of diseases, 12 pipelines, of which the fastest is a First in class:
At present, we are looking forward to the project financing of the anti-tumor CTLA-4 novel peptide vaccine of 10 million yuan. The main United Statesges is to complete the vaccine safety evaluation before the IND. The current anti-tumor CTLA-4 new peptide vaccine, preclinical trials have been nearly completed, and the effect is obvious. We are confident to make new technological innovations in tumor vaccines.

Biostage is a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea.

The company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Our Cellframe technology is based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology to create what may be a revolutionary method of addressing organ damage.

Biostage has been developing its new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). The current platform, based on our Cellframe technology, represents a complete re-engineering of our earlier organ scaffold and cell technology to better stimulate the regenerative properties of each of these organs. Biostage’s Cellframe technology platform is used to create organ specific Cellspan implants. Recent large animal data showed promising results as our Cellframe technology applied to the esophagus achieved the regeneration of esophageal tissue.

Biotrak Capital is a healthcare-focused investment Fund with over 400M USD under management. In china but for global angle.

Top American medical device company

We are a cross-border private equity fund dedicated to actively pursuing primarily late stage U.S healthcare companies that will benefit from penetrating the vast Asian healthcare market. We identify the well-managed western companies with advanced technology or systems to disrupt the global healthcare market, especially the ones with great market potential in Asia.

A pharmaceutical company

An investment firm focused on early-stage Biotech and MedTech startups.

Healthcare Venture Capital Fund headquartered in Shangahi

国家纳米科学院与广东